BRISBANE, Calif.--(BUSINESS WIRE)--Tercica, Inc. (Nasdaq:TRCA) today reported that its partner IPSEN (Euronext; IPN) received notice that the U.S. Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for Somatuline® Autogel® (60, 90, 120 mg) in the United States as a 28-day sustained-release formulation to treat patients with acromegaly. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, Tercica expects the FDA will complete its review or otherwise respond to the Somatuline® Autogel® NDA by August 30, 2007.
